Sk Biopharmaceuticals Co Ltd (326030) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.019x

Based on the latest financial reports, Sk Biopharmaceuticals Co Ltd (326030) has a cash flow conversion efficiency ratio of 0.019x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩17.92 Billion ≈ $12.14 Million USD) by net assets (₩932.05 Billion ≈ $631.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 326030 market cap overview for the company's overall valuation and market capitalisation.

Sk Biopharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Sk Biopharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Sk Biopharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sk Biopharmaceuticals Co Ltd ranked by their cash flow conversion efficiency. Explore Sk Biopharmaceuticals Co Ltd (326030) cash flow quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Dun & Bradstreet Holdings Inc. NYSE:DNB	0.023x
Hyundai Motor Co Pref KO:005387	-0.039x
Xiamen Faratronic Co Ltd SHG:600563	0.036x
PBF Energy Inc NYSE:PBF	0.005x
Turkcell Iletisim Hizmetleri A.S F:TUL1	0.093x
Anhui Yingliu SHG:603308	0.017x
Holy Stone Enterprise Co Ltd TW:3026	0.033x
Jiangxi Zhengbang Technology Co Ltd SHE:002157	0.025x

Annual Cash Flow Conversion Efficiency for Sk Biopharmaceuticals Co Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Sk Biopharmaceuticals Co Ltd from 2016 to 2025. View 326030 stock price and chart for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩826.27 Billion ≈ $559.95 Million	₩176.33 Billion ≈ $119.50 Million	0.213x	+29.08%
2024-12-31	₩573.98 Billion ≈ $388.98 Million	₩94.90 Billion ≈ $64.31 Million	0.165x	+156.33%
2023-12-31	₩320.95 Billion ≈ $217.50 Million	₩-94.20 Billion ≈ $-63.84 Million	-0.294x	+41.90%
2022-12-31	₩316.56 Billion ≈ $214.53 Million	₩-159.92 Billion ≈ $-108.38 Million	-0.505x	-141.62%
2021-12-31	₩444.19 Billion ≈ $301.02 Million	₩-92.87 Billion ≈ $-62.94 Million	-0.209x	+62.39%
2020-12-31	₩379.07 Billion ≈ $256.89 Million	₩-210.73 Billion ≈ $-142.81 Million	-0.556x	-108.90%
2019-12-31	₩-13.03 Billion ≈ $-8.83 Million	₩-81.33 Billion ≈ $-55.12 Million	6.244x	+359.13%
2018-12-31	₩58.63 Billion ≈ $39.73 Million	₩-141.28 Billion ≈ $-95.74 Million	-2.410x	-15.76%
2017-12-31	₩47.24 Billion ≈ $32.02 Million	₩-98.34 Billion ≈ $-66.65 Million	-2.082x	-528.17%
2016-12-31	₩147.69 Billion ≈ $100.09 Million	₩-48.94 Billion ≈ $-33.17 Million	-0.331x	--

About Sk Biopharmaceuticals Co Ltd

KO:326030 Korea Biotechnology

Market Cap

$4.08 Billion

₩6.02 Trillion KRW

Market Cap Rank

#4098 Global

#92 in Korea

Share Price

₩76900.00

Change (1 day)

-0.90%

52-Week Range

₩74600.00 - ₩140700.00

All Time High

₩217000.00